SCHEMBL3013134

SCHEMBL3013134

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.39
OXTR P30559 4/20 0.37
AVPR1A P37288 4/20 0.37
AVPR1B P47901 4/20 0.37
NPC1 O15118 2/20 0.37
POLB P06746 2/20 0.36
ALDH1A1 P00352 3/20 0.36
ADORA1 P30542 1/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
ENPP2 Q13822 1/20 0.36
KCNQ1 P51787 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010954 0.93 KCNQ1 (0.42) RAB9ASMN1; SMN2MAPTNPC1ALDH1A1
SCHEMBL3002254 0.93 SMN1; SMN2 (0.42) RAB9ASMN1; SMN2MAPTOXTRAVPR1A
SCHEMBL3011323 0.91 RAB9A (0.35) RAB9ASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3011307 0.91 MAPT (0.41) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL3016582 0.90 MAPT (0.40) RAB9ASMN1; SMN2MAPTNPC1LMNA
SCHEMBL2997801 0.90 SMN1; SMN2 (0.39) RAB9ASMN1; SMN2MAPTOXTRAVPR1A
SCHEMBL3010085 0.90 MAPT (0.43) MAPTPOLBALDH1A1LMNAMAPK1
SCHEMBL3013116 0.89 MAPT (0.39) RAB9ASMN1; SMN2MAPTOXTRAVPR1A
SCHEMBL3006962 0.89 SMN1; SMN2 (0.35) RAB9ASMN1; SMN2MAPTNPC1POLB
SCHEMBL3003648 0.89 SMN1; SMN2 (0.38) RAB9ASMN1; SMN2MAPTNPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.